Time is of the essence to convince Congress it’s time to finish the PBM reform work it started. Now more than ever, PBM profits are soaring while they make people pay more for their medicines and make it impossible for pharmacies of any size to stay open. People and communities across this country rely on their pharmacies. The clock is ticking for Congress to pass real PBM reform for Medicare and Medicaid. See the NACDS television ad warning against squandering the chance to protect Americans’ access to the pharmacies and pharmacists they trust and rely upon.
PBM reforms passed by the U.S. House of Representatives and House Energy and Commerce Committee will help advance PBM reform. But the substantial Medicaid and Medicare reforms by the U.S. Senate Finance Committee will go even further to help offset the negative effects on Americans and on pharmacies caused by pharmaceutical benefit manipulation. The Senate panel’s bipartisan package adds important components to the Committee-passed Modernizing and Ensuring PBM Accountability Act. Collectively, these policies embody not only Medicaid reforms of the NACDS-backed Drug Price Transparency in Medicaid Act, but also Medicare reforms of the NACDS-backed Neighborhood Options for Patients Buying Medicines (NO PBMs) Act like the must-have ability to ensure “reasonable and relevant” PBM contract terms in Medicare Part D, strong Centers for Medicare & Medicaid Services enforcement provisions, and pharmacy quality measures/PBM transparency.
In fact, a December letter from the Centers for Medicare & Medicaid Services to PBMs and plans challenges PBM and plan tactics saying they “threaten the sustainability of many pharmacies, impede access to care, and put increased burden on healthcare providers.”
We are hearing reports that the predatory tactics of PBMs have become even worse in 2024. NACDS RxIMPACT needs your help TODAY to tell Congress to finish what it started and enact REAL PBM REFORM at the federal level that protects Americans on Medicare and Medicaid and their pharmacies!
Simply enter your contact information in the right column and the system will generate a personalized communication to your Representative and two Senators. If you have any questions or would like any assistance, please contact Heidi Ecker via telephone at 703-837-4121 or email.
PBM reforms passed by the U.S. House of Representatives and House Energy and Commerce Committee will help advance PBM reform. But the substantial Medicaid and Medicare reforms by the U.S. Senate Finance Committee will go even further to help offset the negative effects on Americans and on pharmacies caused by pharmaceutical benefit manipulation. The Senate panel’s bipartisan package adds important components to the Committee-passed Modernizing and Ensuring PBM Accountability Act. Collectively, these policies embody not only Medicaid reforms of the NACDS-backed Drug Price Transparency in Medicaid Act, but also Medicare reforms of the NACDS-backed Neighborhood Options for Patients Buying Medicines (NO PBMs) Act like the must-have ability to ensure “reasonable and relevant” PBM contract terms in Medicare Part D, strong Centers for Medicare & Medicaid Services enforcement provisions, and pharmacy quality measures/PBM transparency.
In fact, a December letter from the Centers for Medicare & Medicaid Services to PBMs and plans challenges PBM and plan tactics saying they “threaten the sustainability of many pharmacies, impede access to care, and put increased burden on healthcare providers.”
We are hearing reports that the predatory tactics of PBMs have become even worse in 2024. NACDS RxIMPACT needs your help TODAY to tell Congress to finish what it started and enact REAL PBM REFORM at the federal level that protects Americans on Medicare and Medicaid and their pharmacies!
Simply enter your contact information in the right column and the system will generate a personalized communication to your Representative and two Senators. If you have any questions or would like any assistance, please contact Heidi Ecker via telephone at 703-837-4121 or email.